**Supplementary table 2.** Unadjusted and adjustedstandard dose inactivated influenza vaccine effectiveness (VE) against A(H3N2) viruses (excluding 2014-15 season) restricted to persons with fever or those with documented vaccination status only.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **18-49 years** | **50-64 years** | **65-74 years** | **≥75 years** | **≥65 years** |
|  | Cases, n | aVE\*(95% CI) | Effect modification p value†  | Cases, n | aVE\*(95% CI) | Effect modification p value  | Cases, n | aVE\*(95% CI) | Effect modification p value  | Cases, n | aVE\*(95% CI) | Effect modification p value | Cases, n | aVE\*(95% CI) | Effect modification p value  |
| **Fever** | 563 | 32(16, 43) | -  | 248 | 53(36, 66) | 0.12 | 91 | 31(-39, 66) | 0.96 | 54 | 19(-144, 73) | 0.88 | 145 | 30(-21, 60) | 0.77 |
| **Documented vaccination**  | 638 | 35(21, 47) | - | 296 | 54(39, 65) | 0.13 | 118 | 9.0(-54, 46) | 0.31 | 88 | 32(-45, 68) | 0.84 | 206 | 16(-27, 45) | 0.24 |

\*Adjusted for US Flu VE Network site, age (by month spline), month of enrollment, sex, race/ethnicity, presence of ≥1 high-risk condition, self-rated health status, interval from symptom onset to enrollment, season

†p value for the interaction term of age and vaccination (for the test of significance of the interaction term) in model using adults aged 18-49 years as the comparison group